Synthetic vaccine
A synthetic vaccine is a
History
The world's first synthetic vaccine was created in 1796 from
In 1986, Manuel Elkin Patarroyo created the SPf66, the first version of a synthetic vaccine for Malaria.[1]
During the H1N1 outbreak in 2009, vaccines only became available in large quantities after the peak of human infections. This was a learning experience for vaccination companies. Novartis Vaccine and Diagnostics, among other companies, developed a synthetic approach that very rapidly generates vaccine viruses from sequence data in order to be able to administer vaccinations early in the pandemic outbreak. Philip Dormatizer, the leader of viral vaccine research at Novartis, says they have "developed a way of chemically synthesizing virus genomes and growing them in tissue culture cells".[2]
Phase I data of UB-311, a synthetic peptide vaccine targeting amyloid beta, showed that the drug was able to generate antibodies to specific amyloid beta oligomers and fibrils with no decrease in antibody levels in patients of advanced age. Results from the Phase II trial are expected in the second half of 2018.[3][4]
References
- PMID 17403557.
- ^ Young Rojahn, Susan (May 14, 2013). "Synthetic Biology Could Speed Flu Vaccine Production". MIT Technology Review.
- ^ "Archived copy". Archived from the original on 2019-06-17. Retrieved 2017-11-09.
{{cite web}}: CS1 maint: archived copy as title (link)[full citation needed] - PMID 29067332.